相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy
Raja Ramachandran et al.
KIDNEY INTERNATIONAL REPORTS (2021)
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
Steven Le Gouill et al.
BLOOD (2021)
New 'Antigens' in Membranous Nephropathy
Sanjeev Sethi
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
KDIGO 2021 CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF GLOMERULAR DISEASES
Brad H. Rovin et al.
KIDNEY INTERNATIONAL (2021)
Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PL A2R1-associated membranous nephropathy
George Haddad et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Advances in Membranous Nephropathy
Pierre Ronco et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
Maxime Teisseyre et al.
FRONTIERS IN IMMUNOLOGY (2021)
Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy
Marion Delafosse et al.
KIDNEY INTERNATIONAL (2021)
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy
Gema Fernandez-Juarez et al.
KIDNEY INTERNATIONAL (2021)
PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis
Laurence H. Beck et al.
KIDNEY INTERNATIONAL REPORTS (2021)
Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy
Maxime Teisseyre et al.
KIDNEY INTERNATIONAL REPORTS (2021)
Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy
Sofiane Salhi et al.
KIDNEY INTERNATIONAL (2021)
Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy
Christine Barrett et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy
Alice Combier et al.
RHEUMATOLOGY (2020)
Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy
Linda Reinhard et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
Sonia Boyer-Suavet et al.
FRONTIERS IN IMMUNOLOGY (2020)
Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial
Vesna Brglez et al.
FRONTIERS IN MEDICINE (2020)
Complement Pathways in Membranous Nephropathy: Complex and Multifactorial
Vesna Brglez et al.
KIDNEY INTERNATIONAL REPORTS (2020)
Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy
Supreet Sethi et al.
KIDNEY INTERNATIONAL REPORTS (2020)
Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies
S. Casertano et al.
EUROPEAN JOURNAL OF NEUROLOGY (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy
David G. Maloney et al.
BLOOD ADVANCES (2020)
Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy
Gian Marco Ghiggeri et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
Muhammad Sadeqi Nezhad et al.
FRONTIERS IN IMMUNOLOGY (2020)
Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses
Marion Cremoni et al.
FRONTIERS IN IMMUNOLOGY (2020)
Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab
Manuel Alfredo Podesta et al.
NEPHRON (2020)
Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients
Yingkai Li et al.
EXPERIMENTAL NEUROLOGY (2019)
Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy
Christelle Zaghrini et al.
KIDNEY INTERNATIONAL (2019)
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
Rita Kansal et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Rituximab bioavailability in primary membranous nephropathy
Sonia Boyer-Suavet et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy
Barbara Seitz-Polski et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
F. C. Fervenza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Treatment of Membranous Nephropathy in Patients With THSD7A Antibodies Using Immunoadsorption
Julia Weinmann-Menke et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2019)
Complement Inhibitors in Clinical Trials for Glomerular Diseases
Peter F. Zipfel et al.
FRONTIERS IN IMMUNOLOGY (2019)
Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy
Uma Fogueri et al.
ANNALS OF PHARMACOTHERAPY (2019)
Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody
K. Dahan et al.
KIDNEY INTERNATIONAL (2019)
Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation
Mael Lateb et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
Rituximab or Cyclosporine for Membranous Nephropathy
Meryl Waldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy
Lida M. Rodas et al.
CLINICAL KIDNEY JOURNAL (2019)
Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy
Barbara Seitz-Polski et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
The Most N-Terminal Region of THSD7A Is the Predominant Target for Autoimmunity in THSD7A-Associated Membranous Nephropathy
Larissa Seifert et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Primary glomerular nephropathy among hospitalized patients in a national database in China
Jiannan Li et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
Howard Trachtman et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy
Elion Hoxha et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Karine Dahan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy
Jan A. J. G. van den Brand et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab
Michelle Rosenzwajg et al.
KIDNEY INTERNATIONAL (2017)
Treatment of membranous nephropathy: time for a paradigm shift
Piero Ruggenenti et al.
NATURE REVIEWS NEPHROLOGY (2017)
Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years
Franck Pourcine et al.
PLOS ONE (2017)
Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy
Perrine Jullien et al.
CLINICAL KIDNEY JOURNAL (2017)
Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy
Barbara Seitz-Polski et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature
D. Roccatello et al.
AUTOIMMUNITY REVIEWS (2016)
Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China
Xin Xu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Expanding antigen-specific regulatory networks to treat autoimmunity
Xavier Clemente-Casares et al.
NATURE (2016)
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Christoph T. Ellebrecht et al.
SCIENCE (2016)
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
Gemma Currie et al.
BMC NEPHROLOGY (2016)
Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab
Meryl Waldman et al.
KIDNEY INTERNATIONAL REPORTS (2016)
Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy
Sjoerd A. M. E. G. Timmermans et al.
AMERICAN JOURNAL OF NEPHROLOGY (2015)
A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis
Janina Mueller-Deile et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2015)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
Piero Ruggenenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells
Lorenzo Gallon et al.
TRANSPLANTATION (2015)
Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Venkat Reddy et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Identification of the Immunodominant Epitope Region in Phospholipase A2 Receptor-Mediating Autoantibody Binding in Idiopathic Membranous Nephropathy
Liyo Kao et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Identification of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous Nephropathy
Maryline Fresquet et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
M-type Phospholipase A2 Receptor Autoantibodies and Renal Function in Patients with Primary Membranous Nephropathy
Elion Hoxha et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy
Choli Hartono et al.
JOURNAL OF NEPHROLOGY (2014)
Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients with Primary Membranous Nephropathy
Elion Hoxha et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells
Dan Blat et al.
MOLECULAR THERAPY (2014)
Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy
Nicola M. Tomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Diagnosis Accuracy of PLA2R-AB in the Diagnosis of Idiopathic Membranous Nephropathy: A Meta-Analysis
Yu Du et al.
PLOS ONE (2014)
PLA2R Antibody Levels and Clinical Outcome in Patients with Membranous Nephropathy and Non-Nephrotic Range Proteinuria under Treatment with Inhibitors of the Renin-Angiotensin System
Elion Hoxha et al.
PLOS ONE (2014)
Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy
Durga Kanigicherla et al.
KIDNEY INTERNATIONAL (2013)
Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies
Christophe Passot et al.
MABS (2013)
Treatment of Resistant Glomerular Diseases with Adrenocorticotropic Hormone Gel: A Prospective Trial
Andrew S. Bomback et al.
AMERICAN JOURNAL OF NEPHROLOGY (2012)
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
Moa Fransson et al.
JOURNAL OF NEUROINFLAMMATION (2012)
Rituximab in Idiopathic Membranous Nephropathy
Piero Ruggenenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy
Julia M. Hofstra et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy
Sean H. Lim et al.
BLOOD (2011)
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
Michaela Patz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Low-Molecular-Weight Proteins as Prognostic Markers in Idiopathic Membranous Nephropathy
Jan A. J. G. van den Brand et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy
Julia M. Hofstra et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens
Maurizio Bruschi et al.
JOURNAL OF PROTEOMICS (2011)
Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis
R. M. Thurlings et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
Stephen A. Beers et al.
BLOOD (2010)
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fernando C. Fervenza et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Autoimmunity in Membranous Nephropathy Targets Aldose Reductase and SOD2
Marco Prunotto et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Alkylating agents in membranous nephropathy: efficacy proven beyond doubt
Julia M. Hofstra et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Effects and Mechanisms of Tacrolimus on Development of Murine Th17 Cells
X. -J. Zhang et al.
TRANSPLANTATION PROCEEDINGS (2010)
M-Type Phospholipase A(sub 2) Receptor as Target Antigen in Idiopathic Membranous Nephropathy.
Laurence H. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan
Liffert Vogt et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Rituximab treatment of idiopathic membranous nephropathy
F. C. Fervenza et al.
KIDNEY INTERNATIONAL (2008)
Intramolecular epitope spreading in Heymann nephritis
Pallavi Shah et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy
A Kuroki et al.
KIDNEY INTERNATIONAL (2005)
Cellular response to injury in membranous nephropathy
M Nangaku et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents
VLM Esnault et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Urinary excretion of beta 2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: A validation study
AJW Branten et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan
H Shiiki et al.
KIDNEY INTERNATIONAL (2004)
Rituximab for idiopathic membranous nephropathy
G Remuzzi et al.
LANCET (2002)
Epitope spreading in immunemediated diseases: Implications for immunotherapy
CL Vanderlugt et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Use of mycophenolate mofetil in resistant membranous nephropathy
G Miller et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2000)
分享论文
